ReferenceID 2013
Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy
Acta Pharmacol Sin
Harmine is a beta-carboline alkaloid isolated from Banisteria caapi and Peganum harmala L with various pharmacological activities, including antioxidant, anti-inflammatory, antitumor, anti-depressant, and anti-leishmania
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 2013
- Evidence Id
- 18603
- Core Evidence Id
- 18603
- Source Reference Id
- 4036
- Herb2 Reference Id
- HBREF004833
- Subject Paper Key
- HBIN028803_33785860
- Pubmed Id
- 33785860
- Doi
- 10.1038/s41401-021-00639-y
- Paper Title
- Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy
- Paper Abstract
- Harmine is a beta-carboline alkaloid isolated from Banisteria caapi and Peganum harmala L with various pharmacological activities, including antioxidant, anti-inflammatory, antitumor, anti-depressant, and anti-leishmanial capabilities. Nevertheless, the pharmacological effect of harmine on cardiomyocytes and heart muscle has not been reported. Here we found a protective effect of harmine on cardiac hypertrophy in spontaneously hypertensive rats in vivo. Further, harmine could inhibit the phenotypes of norepinephrine-induced hypertrophy in human embryonic stem cell-derived cardiomyocytes in vitro. It reduced the enlarged cell surface area, reversed the increased calcium handling and contractility, and downregulated expression of hypertrophy-related genes in norepinephrine-induced hypertrophy of human cardiomyocytes derived from embryonic stem cells. We further showed that one of the potential underlying mechanism by which harmine alleviates cardiac hypertrophy relied on inhibition of NF-kappaB phosphorylation and the stimulated inflammatory cytokines in pathological ventricular remodeling. Our data suggest that harmine is a promising therapeutic agent for cardiac hypertrophy independent of blood pressure modulation and could be a promising addition of current medications for cardiac hypertrophy.
- Journal
- Acta Pharmacol Sin
- Publish Year
- 2022
- Experiment Subject
- rat; human
- Experiment Type
- Animal & Cell Experiment
- Phenotype Related
- Cardiac Hypertrophy
- Paper Title Cn
- Paper Title En
- Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy
- Bilingual Status
- semi_complete